About MaxCyte
MaxCyte is a company based in Gaithersburg (United States) founded in 1998. MaxCyte has raised $20.69 million across 14 funding rounds from investors including HHS, Harbert Management and Casdin Capital. The company has 114 employees as of December 31, 2024. MaxCyte has completed 1 acquisition, including SeQure Dx. MaxCyte offers products and services including Electroporation Systems, Processing Assemblies, and Reagents. MaxCyte operates in a competitive market with competitors including SQZBiotech, Gemini Bio, Fluxion Biosciences, Berkeley Lights and LBT Innovations, among others.
- Headquarter Gaithersburg, United States
- Employees 114 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Maxcyte, Inc.
-
Annual Revenue
$38.63 M (USD)-6.44as on Dec 31, 2024
-
Net Profit
-$41.05 M (USD)-8.26as on Dec 31, 2024
-
EBITDA
-$46.74 M (USD)-6.13as on Dec 31, 2024
-
Total Equity Funding
$20.69 M (USD)
in 14 rounds
-
Latest Funding Round
$31.42 M (USD), Post-IPO
May 01, 2020
-
Investors
HHS
& 6 more
-
Employee Count
114
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of MaxCyte
MaxCyte is a publicly listed company on the NASDAQ with ticker symbol MXCT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of MaxCyte
MaxCyte offers a comprehensive portfolio of products and services, including Electroporation Systems, Processing Assemblies, and Reagents.
Devices for efficient cell transfection in therapy and research
Components for scalable electroporation workflows
Buffers and accessories for cell engineering processes
People of MaxCyte
Unlock access to complete
Unlock access to complete
Funding Insights of MaxCyte
MaxCyte has successfully raised a total of $20.69M across 14 strategic funding rounds. The most recent funding activity was a Post-IPO round of $31.42 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in MaxCyte
MaxCyte has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Harbert Management and Casdin Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked | |
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Locked | Locked | Locked | |
|
Stem cell research startups in healthcare are funded and accelerated.
|
Locked | Locked | Locked |
Investor details for MaxCyte
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MaxCyte
MaxCyte has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include SeQure Dx.
Investment portfolio details for MaxCyte
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of personalized diagnostics for gene-editing therapies
|
Locked | Locked | 2020 | Locked |
Complete acquisition details for MaxCyte
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - MaxCyte
Detailed financials for MaxCyte
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Maxcyte Comparisons
Peer comparison for MaxCyte
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MaxCyte
MaxCyte operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as SQZBiotech, Gemini Bio, Fluxion Biosciences, Berkeley Lights and LBT Innovations, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cell therapies are developed using proprietary Cell Squeeze technology.
|
|
| Locked | Locked | Locked |
Supplement reagents for cell and gene therapy are manufactured.
|
|
| Locked | Locked | Locked |
Microfluidics-based tools for cellular analysis are provided.
|
|
| Locked | Locked | Locked |
Microfluidics-based systems for single-cell isolation and analysis are developed.
|
|
| Locked | Locked | Locked |
Developer of AI-based automated solutions for the preparation and analysis of microbiology culture specimens
|
Detailed competitors of MaxCyte
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Maxcyte
Complete news archive for MaxCyte
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MaxCyte
MaxCyte was founded in 1998 and raised its 1st funding round 6 years after it was founded.
MaxCyte is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
MaxCyte is a funded company, having raised a total of $20.69M across 14 funding rounds to date.
As of Dec 31, 2024, the latest employee count at MaxCyte is 114.
Annual revenue of MaxCyte is $38.63M as on Dec 31, 2024.
MaxCyte was founded in 1998 and is headquartered in Gaithersburg, United States. Operations focus on the biotechnology sector, where instrument systems for cell processing and modification are developed and supplied. Key products include the MaxCyte STX, a flow electroporation-based system for single transfections, and the MaxCyte VLX for large-volume transient transfections. Additional services encompass transfection insourcing, such as producing cells with targets of interest and recombinant proteins.
MaxCyte's top competitors include SQZBiotech, Mytos and Thrive Bioscience.
MaxCyte offers Electroporation Systems, Processing Assemblies, and Reagents.
Yes, MaxCyte is publicly traded on NASDAQ under the ticker symbol MXCT.
MaxCyte has made 1 acquisition, including SeQure Dx.
MaxCyte has 7 investors. Key investors include HHS, Harbert Management, Casdin Capital, Sofinnova Partners, and Maryland Stem Cell Research Fund.
The ticker symbol of MaxCyte is MXCT on NASDAQ.